Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Yuhan Corporation Preferred Stock (000105:KRX), powered by AI.
Yuhan Corporation Preferred Stock is currently trading at ₩66,200. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Yuhan Corporation Preferred Stock on Alpha Lenz.
Yuhan Corporation Preferred Stock's P/E ratio is 0.4.
“Yuhan Corporation Preferred Stock trades at a P/E of 0.4 (undervalued) with solid ROE of 8.8%.”
Ask for details →Yuhan Corporation Preferred Stock represents a class of shares issued by Yuhan Corporation, a South Korean pharmaceutical and healthcare company. This type of stock gives investors a higher claim on the company's assets and earnings compared to common stockholders. With preferred shares, investors typically receive fixed dividends that are paid out before any dividends on the company's common stock are issued. Yuhan Corporation is renowned for its production of pharmaceuticals, biotechnology products, and health supplements, contributing significantly to sectors such as healthcare, life sciences, and pharmaceuticals. The preferred stock is particularly suited for stakeholders seeking more stable income through dividends, due to its prioritized payout structure. In the financial market, Yuhan Corporation Preferred Stock plays a vital role by offering investors an instrument that balances growth potential in the healthcare industry with the relatively secure returns of preferred dividends. This stock therefore attracts both institutional and individual investors focusing on stable income with reduced risk, as they participate indirectly in the burgeoning pharmaceutical sector of South Korea.
“Yuhan Corporation Preferred Stock trades at a P/E of 0.4 (undervalued) with solid ROE of 8.8%.”
Ask for details →Yuhan Corporation Preferred Stock (ticker: 000105) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 2,038 employees. Market cap is $78.2B.
The current price is ₩66,200 with a P/E ratio of 0.4x and P/B of 0.03x.
ROE is 8.81% and operating margin is 4.77%. Annual revenue is $2.2T.